4.7 Review

Diabetes in Asia Epidemiology, Risk Factors, and Pathophysiology

期刊

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 301, 期 20, 页码 2129-2140

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2009.726

关键词

-

资金

  1. AstraZeneca
  2. Bayer
  3. Bristol-Myers Squibb
  4. Daiichi-Sankyo
  5. GlaxoSmithKline
  6. Lilly
  7. Merck Serono
  8. Merck Sharp Dohme
  9. Novo Nordisk
  10. Pfizer
  11. Roche
  12. sanofiaventis
  13. National Research Foundation of Korea [전06A1101] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

Context With increasing globalization and East-West exchanges, the increasing epidemic of type 2 diabetes in Asia has far-reaching public health and socioeconomic implications. Objective To review recent data in epidemiologic trends, risk factors, and complications of type 2 diabetes in Asia. Evidence Acquisition Search of MEDLINE using the term diabetes and other relevant keywords to identify meta-analyses, systematic reviews, large surveys, and cohort studies. Separate searches were performed for specific Asian countries. The review was limited to English-language articles published between January 1980 and March 2009; publications on type 1 diabetes were excluded. Evidence Synthesis The prevalence of diabetes in Asian populations has increased rapidly in recent decades. In 2007, more than 110 million individuals in Asia were living with diabetes, with a disproportionate burden among the young and middle aged. Similarly, rates of overweight and obesity are increasing sharply, driven by economic development, nutrition transition, and increasingly sedentary lifestyles. The metabolically obese phenotype (ie, normal body weight with increased abdominal adiposity) is common in Asian populations. The increased risk of gestational diabetes, combined with exposure to poor nutrition in utero and overnutrition in later life in some populations, may contribute to the increasing diabetes epidemic through diabetes begetting diabetes in Asia. While young age of onset and long disease duration place Asian patients with diabetes at high risk for cardiorenal complications, cancer is emerging as an important cause of morbidity and mortality. Conclusions Type 2 diabetes is an increasing epidemic in Asia, characterized by rapid rates of increase over short periods and onset at a relatively young age and low body mass index. Prevention and control of diabetes should be a top public health priority in Asian populations. JAMA. 2009;301(20):2129-2140 www.jama.com

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据